Key Points
- Director Michael Hoffman purchased 713,800 shares at an average cost of $2.10 each (≈$1.499M), increasing his holding to 3,288,539 shares — a 27.72% boost.
- ANVS trades near $2.28 with a market cap of about $64.5M; the company reported a Q EPS of -$0.39 (missed estimates), and the stock carries a consensus "Hold" rating with an average price target of $13.50.
- Annovis is a clinical-stage biotech focused on neurodegenerative diseases, with lead asset ANVS401 (Posiphen) under development for Alzheimer's and related disorders.
Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman acquired 713,800 shares of the firm's stock in a transaction dated Thursday, April 2nd. The shares were purchased at an average cost of $2.10 per share, with a total value of $1,498,980.00. Following the completion of the transaction, the director owned 3,288,539 shares in the company, valued at approximately $6,905,931.90. The trade was a 27.72% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Annovis Bio Trading Down 0.2%
ANVS stock opened at $2.28 on Friday. The stock has a market cap of $64.50 million, a P/E ratio of -1.63 and a beta of 1.37. Annovis Bio, Inc. has a twelve month low of $1.11 and a twelve month high of $5.50. The company's 50 day moving average is $2.52 and its two-hundred day moving average is $2.83.
Annovis Bio (NYSE:ANVS - Get Free Report) last posted its earnings results on Friday, March 13th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). On average, equities research analysts predict that Annovis Bio, Inc. will post -2.19 earnings per share for the current year.
Hedge Funds Weigh In On Annovis Bio
A number of institutional investors and hedge funds have recently bought and sold shares of ANVS. JPMorgan Chase & Co. increased its holdings in Annovis Bio by 69.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 14,900 shares of the company's stock worth $32,000 after purchasing an additional 6,100 shares during the last quarter. RKL Wealth Management LLC acquired a new stake in shares of Annovis Bio during the fourth quarter worth approximately $35,000. RFG Advisory LLC bought a new stake in shares of Annovis Bio in the fourth quarter worth $43,000. Wells Fargo & Company MN increased its stake in shares of Annovis Bio by 46.8% in the fourth quarter. Wells Fargo & Company MN now owns 14,307 shares of the company's stock worth $50,000 after buying an additional 4,561 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Annovis Bio during the second quarter worth about $52,000. Hedge funds and other institutional investors own 15.83% of the company's stock.
Analyst Ratings Changes
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Annovis Bio in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $13.50.
Check Out Our Latest Research Report on Annovis Bio
Annovis Bio Company Profile
(
Get Free Report)
Annovis Bio, Inc (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company's pipeline is designed to address critical pathways implicated in Alzheimer's disease, Parkinson's disease, multiple sclerosis and other central nervous system conditions.
The company's lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer's patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
